Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0149521 (
chronic pancreatitis
)
7,199
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
SPARC-like protein 1
(
SPARCL1
), a member of the SPARC family, is downregulated in various tumors. In the present study, the expression and localization of
SPARCL1
were analyzed in a wide range of nontumorous and neoplastic pancreatic tissues by quantitative reverse transcription-polymerase chain reaction, laser capture microdissection, microarray analysis, and immunohistochemistry. For functional analysis, proliferation and invasion assays were used in cultured pancreatic cancer cells. Pancreatic ductal adenocarcinoma (PDAC) and other pancreatic neoplasms exhibited increased
SPARCL1
mRNA levels compared to those of the normal pancreas.
SPARCL1
mRNA levels were low to absent in microdissected and cultured pancreatic cancer cells, and promoter demethylation increased
SPARCL1
levels only slightly in three of eight cell lines.
SPARCL1
was observed in small capillaries in areas of inflammation/tumor growth and in some islet cells. In PDAC, 15.4% of vessels were
SPARCL1
-positive. In contrast, the percentage of
SPARCL1
-positive vessels was higher in
chronic pancreatitis
and benign and borderline pancreatic tumors. Recombinant
SPARCL1
inhibited pancreatic cancer cell invasion and exerted moderate growth-inhibitory effects. In conclusion,
SPARCL1
expression in pancreatic tissues is highly correlated with level of vascularity. Its anti-invasive effects and reduced expression in metastasis indicate tumor-suppressor function.
...
PMID:Tumor-suppressor function of SPARC-like protein 1/Hevin in pancreatic cancer. 1732 39